Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Catherine H Smith

Showing results (1-10 of 169) with videos related to

Pageof 17
Sort By:
Expert Review of Clinical Immunology|October 29, 2010
How genetic variation affects patient response and outcome to therapy for psoriasisRichard T Woolf, Catherine H Smith
Archives of Dermatology|August 23, 2006
Acute severe blistering in a 24-year-old man: phytophotodermatitis, caused by contact with limeE Mary Wain, Catherine H Smith
Clinical Medicine (London, England)|April 10, 2014
Psoriasis: guidance on assessment and referralEleanor J Samarasekera, Catherine H Smith, , et al.
Lancet (London, England)|August 13, 2019
Psoriasis biologics: a new era of choiceSatveer K Mahil, Catherine H Smith
Archives of Dermatology|December 19, 2007
British guidelines on the use of biological therapies for psoriasis: a note of clarification on the role of etanerceptCatherine H Smith, Anthony D Ormerod
Annals of Internal Medicine|November 16, 2020
In chronic plaque psoriasis, roflumilast cream safely increased likelihood of clear or almost clear state at 6 weeksSatveer K Mahil, Catherine H Smith
BMJ (Clinical Research Ed.)|August 19, 2006
Psoriasis and its managementCatherine H Smith, J N W N Barker
The British Journal of Dermatology|February 10, 2023
Spesolimab in the treatment of generalized pustular psoriasis: a critically appraised research paperFatima Ali, Catherine H Smith, Satveer K Mahil
BMJ (Clinical Research Ed.)|March 29, 2011
Life threatening myelotoxicity secondary to azathioprine in a patient with atopic eczema and normal thiopurine methyltransferase activityJamie S Wee, Anthony Marinaki, Catherine H Smith
The British Journal of Dermatology|November 4, 2025
Psoriasis at high-impact sites: shifting the paradigmTeresa Tsakok, Zenas Z N Yiu, Catherine H Smith
Pageof 17

Showing results (1-10 of 169) with videos related to

Sort By:
Pageof 17
Expert Review of Clinical Immunology|October 29, 2010
How genetic variation affects patient response and outcome to therapy for psoriasisRichard T Woolf, Catherine H Smith
Archives of Dermatology|August 23, 2006
Acute severe blistering in a 24-year-old man: phytophotodermatitis, caused by contact with limeE Mary Wain, Catherine H Smith
Clinical Medicine (London, England)|April 10, 2014
Psoriasis: guidance on assessment and referralEleanor J Samarasekera, Catherine H Smith, , et al.
Lancet (London, England)|August 13, 2019
Psoriasis biologics: a new era of choiceSatveer K Mahil, Catherine H Smith
Archives of Dermatology|December 19, 2007
British guidelines on the use of biological therapies for psoriasis: a note of clarification on the role of etanerceptCatherine H Smith, Anthony D Ormerod
Annals of Internal Medicine|November 16, 2020
In chronic plaque psoriasis, roflumilast cream safely increased likelihood of clear or almost clear state at 6 weeksSatveer K Mahil, Catherine H Smith
BMJ (Clinical Research Ed.)|August 19, 2006
Psoriasis and its managementCatherine H Smith, J N W N Barker
The British Journal of Dermatology|February 10, 2023
Spesolimab in the treatment of generalized pustular psoriasis: a critically appraised research paperFatima Ali, Catherine H Smith, Satveer K Mahil
BMJ (Clinical Research Ed.)|March 29, 2011
Life threatening myelotoxicity secondary to azathioprine in a patient with atopic eczema and normal thiopurine methyltransferase activityJamie S Wee, Anthony Marinaki, Catherine H Smith
The British Journal of Dermatology|November 4, 2025
Psoriasis at high-impact sites: shifting the paradigmTeresa Tsakok, Zenas Z N Yiu, Catherine H Smith
Pageof 17